As procurement teams across the NHS and wider healthcare sector place increasing emphasis on proven activity against Clostridioides difficile (C. difficile), EN 17486 is rapidly becoming a key expectation in tenders and technical specifications – it’s a standard no brand supplying into healthcare can afford to ignore. At MSL, we’re supporting manufacturers who need reliable, realworld evidence to meet these evolving requirements.

What is EN17486 and why it matters

EN 17486 sets out a robust method for demonstrating sporicidal efficacy, including activity against C. difficile, under conditions designed to reflect realworld wipe use. Unlike traditional sporicidal tests, which often assess products under idealised laboratory conditions, EN 17486 mirrors practical application.

This gives healthcare buyers greater confidence that a wipe will perform effectively in clinical environments. As a result, EN 17486 is appearing more frequently in procurement documents, signalling a clear shift in buyer expectations.

Our EN 17486 testing service

We’re fully equipped to perform EN 17486 testing and help manufacturers demonstrate the level of sporicidal efficacy healthcare environments now expect. We provide clear, reliable EN 17486 evidence that shows how a wipe performs under real‑world conditions, supporting their tenders and helping strengthen infection‑prevention practices in clinical settings.

For more information or to book a test, please contact us.